Abstract
The approval of tisagenlecleucel and axicabtagene ciloleucel represents a breakthrough in the field of immune and cellular therapy for hematologic malignancies. These anti-CD19 chimeric antigen receptor-T cells (CAR) proved to be highly effective in the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and specific histologic subtypes of B-cell non-Hodgkin lymphomas. This expert review aims to summarize the current available research evidence in this field, with a special focus on the different challenges faced by treating physicians, and we also provide future perspectives.
MeSH terms
-
Antigens, CD19 / immunology*
-
Antigens, Neoplasm / immunology
-
Biomarkers, Tumor
-
Clinical Trials as Topic
-
Genetic Engineering
-
Humans
-
Immunotherapy, Adoptive* / adverse effects
-
Immunotherapy, Adoptive* / methods
-
Leukemia, B-Cell / diagnosis
-
Leukemia, B-Cell / etiology
-
Leukemia, B-Cell / mortality
-
Leukemia, B-Cell / therapy*
-
Lymphoma, B-Cell / diagnosis
-
Lymphoma, B-Cell / etiology
-
Lymphoma, B-Cell / mortality
-
Lymphoma, B-Cell / therapy*
-
Receptors, Chimeric Antigen / genetics
-
Receptors, Chimeric Antigen / metabolism*
-
T-Lymphocytes / immunology*
-
T-Lymphocytes / metabolism*
-
Treatment Outcome
Substances
-
Antigens, CD19
-
Antigens, Neoplasm
-
Biomarkers, Tumor
-
CD19 molecule, human
-
Receptors, Chimeric Antigen